Written question asked by David Anderson (Labour) on Thursday, 19 May 2016, in the House of Commons. It was due for an answer on Monday, 23 May 2016. It was answered by George Freeman (Conservative) on Wednesday, 25 May 2016 on behalf of the Department of Health.
Muscular Dystrophy: Drugs
- Question
-
To ask the Secretary of State for Health, what steps he is taking to ensure that NHS England implements the NICE recommendation for NHS funding for Translarna as a treatment for Duchenne muscular dystrophy.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The expected publication date for NICE’s final guidance is July 2016.
National Health Service commissioners are legally required to fund drugs and treatments recommended in NICE highly specialised technology guidance within three months of its final guidance being issued.
Secondary information
- Type
- Written question
- Reference
- 37645
- Session
- 2016-17
- Subjects
- Finance Drugs Muscular dystrophy Ataluren
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2016-08-11 14:41:58 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/37645
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/37645
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/37645